Segall Bryant & Hamill LLC Sells 25,195 Shares of Bioventus Inc. (NYSE:BVS)

Segall Bryant & Hamill LLC lowered its stake in shares of Bioventus Inc. (NYSE:BVS) by 6.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 352,629 shares of the company’s stock after selling 25,195 shares during the period. Segall Bryant & Hamill LLC’s holdings in Bioventus were worth $3,703,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Bioventus by 18.7% during the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock valued at $25,852,000 after buying an additional 388,174 shares during the last quarter. American Century Companies Inc. lifted its stake in Bioventus by 38.7% during the 4th quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock valued at $9,289,000 after acquiring an additional 246,645 shares in the last quarter. State Street Corp boosted its holdings in Bioventus by 38.8% during the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after acquiring an additional 189,216 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after acquiring an additional 176,442 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Bioventus by 21,256.6% in the third quarter. FMR LLC now owns 166,795 shares of the company’s stock valued at $1,993,000 after purchasing an additional 166,014 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Insider Activity

In other news, CFO Mark Leonard Singleton sold 6,498 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the transaction, the chief financial officer now owns 118,817 shares of the company’s stock, valued at $1,210,745.23. This represents a 5.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert E. Claypoole sold 28,786 shares of Bioventus stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $261,952.60. Following the completion of the sale, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. This trade represents a 30.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,161 shares of company stock valued at $436,364 in the last three months. Company insiders own 32.90% of the company’s stock.

Bioventus Price Performance

BVS opened at $9.09 on Friday. The firm has a market cap of $744.87 million, a P/E ratio of -14.90 and a beta of 0.86. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The firm has a 50-day moving average of $10.09 and a 200 day moving average of $10.98.

Analyst Upgrades and Downgrades

BVS has been the topic of several analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price target on shares of Bioventus in a report on Monday, March 17th. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and upped their target price for the company from $12.00 to $13.00 in a report on Tuesday, December 17th.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.